MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Natco Pharma Rolls Out a new Drug for Heart Ailment

Natco Pharma Rolls Out a new Drug for Heart Ailment

Natco Pharma, a Hyderabad-based pharmaceuticalcompany has rolled out a new drug for treating heart ailments. The new drug is known as Valsartan-sacubitril (under the company’s brand name Valsac).

Valsartan-sacubitril can eliminate the risk of cardiovascular death in patients suffering from congestive heart problem. It helps to relax the blood vessels. The same brand is sold as Entresto by another Pharmaceutical company, Novartis in the US and other countries.

According to a press release by Natco Pharma, 50 mg of Vymada will cost Rs. 45 and 100mg will cost Rs. 55.

As per the government’s app called Pharma Sahi Daam App, 14 tablets (24/26mg) will cost Rs. 977.50. While in the same price, there are other two tablets called Lupin and Cipla available in the market today.

The new launch by Natco Pharma has challenged the country’s largest drug makers, i.e. Novartis in terms of competition. Apart from that, there can be a battle of patents between the two companies since; Novartis sells the same drug under a different name in the US and other countries. In 2017, the drug’s sales were almost $500M and as per analyst, the sales may touch $2.2 billion by 2022.

Earlier, the two companies along with Cipla were engaged in a serious patent battle over an anti-cancer drug called Glivec.

“Novartis is aware that Natco has announced the launch of a generic version of valsartan-sacubitril and is currently evaluating its options,” quoted by a spokesperson for Novartis.

YOU MAY ALSO LIKE

Marketing Partnership: NBA, McDonald’s Will Jointly open NBA Experience Zones India

There is good news for all basketball fans in India. Very soon, NBA themed promotions and experience zones will be launched in India. The announcement...

Dunzo to Raise Funds from Google, others

Dunzo, the app which is trying to make life easier for the people upto some extent plans to raise about Rs. 183 crore from different investors which a...

Sapta Shakti Command Will Be Displaying Defence Technology Equipment at Jaipur Military Station

This event is organised with an aim to provide an opportunity where one and all can experience the developments in the field of defence and security-r...

Samsung is All Set to Roll out Its Galaxy A9 Smartphone On November 20

After Samsung unveiled its new Galaxy A9 smartphone in Singapore last month, the company is all set to launch it in India on November 20. In Singapore...

RECOMMENDED